The cutting edge of anti-ageing science | Venki Ramakrishnan

Demographic Trends and Biological Limits

• The number of centenarians (people over 100) is rising, but the number of supercentenarians (people over 110) is not increasing at the same rate, suggesting a "hard limit" to human lifespan.
• Supercentenarians typically remain healthy and independent until age 110, after which they experience a rapid, systemic collapse leading to death.
• While no physical or chemical law prohibits living beyond 110 (as evidenced by whales and sharks living hundreds of years), humans would require intervention in the aging process itself to surpass this threshold.
• Demographers estimate that eliminating all major diseases of old age (heart disease, cancer, diabetes) would extend average lifespan by only about 15 years, indicating that aging itself is a distinct underlying driver of mortality.
• The record for the oldest verified human is 122 (Jeanne Calment, died 1997); no one has lived past 120 in the subsequent 30 years, despite advances in healthcare.

Evolutionary Origins of Aging

• Aging is not a programmed evolutionary goal to make room for younger generations; rather, it is the result of evolution optimizing for reproductive fitness rather than longevity.
• Species evolve based on trade-offs between investing energy in growth/reproduction versus maintenance/repair; species with high predation risks (e.g., mice) prioritize rapid reproduction, while larger, less vulnerable species (e.g., bats, whales) invest in longevity.
• Aging is fundamentally an accumulation of molecular, cellular, and tissue damage that eventually causes critical systems to fail.
• Evolutionary trade-offs often favor genes beneficial early in life that cause damage later; for example, pathways like insulin-like growth factor (IGF-1) and TOR promote growth and reproduction but drive aging.
• Senescence (cellular aging) acts as an anti-cancer mechanism to prevent damaged cells from dividing indefinitely, but the accumulation of these senescent cells contributes to aging later in life.
• The aging clock resets each generation via three mechanisms: superior DNA repair in germline cells, a rigorous selection process eliminating defective eggs and sperm, and the erasure of epigenetic marks on DNA during embryonic development.

Assessment of Longevity Interventions

• Senolytics: Removing senescent cells from mice has improved healthspan and extended lifespan by 20–30%; this is considered a promising area, though challenges remain in ensuring drug specificity and safety for long-term use in healthy humans.
• Caloric Restriction: Restricting calories (without malnutrition) extends lifespan and healthspan in diverse species by dampening protein synthesis and boosting autophagy (cellular recycling); it activates the TOR and IGF-1 pathways.
• Rapamycin: This drug inhibits the TOR pathway and mimics caloric restriction effects in mice, extending lifespan even when administered to older animals; however, its use in humans is currently limited by side effects like immunosuppression.
• Metformin: A diabetes drug that affects insulin pathways; early studies suggested it might extend lifespan, but subsequent questions and confounding factors (e.g., statin use) have created uncertainty, with large-scale human trials ongoing.
• Sirtuins (Resveratrol): Once a major focus for extending life via compounds like resveratrol (found in red wine), this field has largely collapsed due to failed replication studies and a lack of efficacy in large-scale mouse trials.
• Yamanaka Factors (Cellular Reprogramming): Transient introduction of these factors can partially reverse cellular aging and improve tissue regeneration in mice without causing cancer; this is the only known approach that could potentially reverse aging, though significant safety concerns regarding teratoma formation and oncogenes remain.
• Parabiosis (Young Blood): Experiments show young blood benefits old animals while old blood harms young ones; however, early human trials of this practice showed no measurable benefit, and the detrimental factors in old blood are now a greater focus of research.
• Cryonics: Current technology can preserve single cells and embryos via cryoprotectants, but no organism (not even a mouse) has been successfully frozen and revived; full-body cryonics is currently considered scientifically implausible.

Specific Disease Mechanisms and Therapies

• Dementia/Alzheimer's: The prevailing view is that misfolded proteins (beta-amyloid and tau) form specific filament structures that kill neurons; new therapies aim to use RNA interference (siRNA) to shut down the production of these proteins.
• Cancer Risk: Cancer risk increases with age due to accumulated DNA damage and epigenetic changes; the P53 protein is a critical tumor suppressor that repairs DNA or triggers cell death, and mutations in P53 occur in nearly 50% of all cancers.
• Peto's Paradox: Large animals like elephants and whales have lower cancer rates than small animals despite having more cells; this is attributed to evolutionary adaptations, such as elephants having 20 copies of the P53 gene compared to humans.
• Mitochondria: As "energy factories," mitochondria produce ATP but also generate reactive oxygen species that damage mitochondrial DNA; aging leads to mitochondrial dysfunction, which is addressed by research into enhancing autophagy and mitochondrial regeneration.

Social and Ethical Implications

• Demographic Shift: Increasing lifespan will alter the population pyramid, potentially creating a shortage of young workers to support a larger elderly population unless fertility rates rise or automation/AI compensates.
• Workforce Dynamics: Extended lifespans may require adjustments to retirement ages and career trajectories to prevent older individuals from blocking opportunities for younger generations, necessitating a shift in societal roles for the elderly.
• Inequality: Longevity interventions risk exacerbating economic inequality, as the wealthy will likely access life-extending treatments first; this could lead to a divergence where the rich live significantly longer and accumulate more wealth across generations compared to the poor.
• Current Disparities: In New York City, residents in the richest zip code live an average of 35 years longer than those in the poorest, a gap driven by healthcare, nutrition, and environment that could widen with advanced longevity therapies.
• Feasibility of Reversal: Venky Ramakrishnan posits that while slowing aging is plausible within 20–30 years, doubling human lifespan would require major breakthroughs, particularly in preventing brain aging and neurodegeneration.
• Hype vs. Reality: The field contains a spectrum of rigor; while some interventions (senolytics, cellular reprogramming) show promise, others (Sirtuins, cryonics) are often overhyped or lack evidence, requiring strict clinical trials to establish safety and efficacy for healthy individuals.